Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07219303 · ClinicalTrials.gov registry record · NA

Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer

A NA study of Prostate Cancer (Adenocarcinoma), sponsored by Fox Chase Cancer Center.

Recruiting
Registry status
NA
Development phase
80
Enrollment target
1
Study location

NCT07219303 is a NA study of Prostate Cancer (Adenocarcinoma) that is actively recruiting participants, run by Fox Chase Cancer Center. The registered enrollment target is 80 participants, below the 124-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07219303, a NA study of Prostate Cancer (Adenocarcinoma), is actively recruiting participants, sponsored by Fox Chase Cancer Center.

RECRUITING
Registry status
NA
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to evaluate if adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time. The main questions this trial aims to answer are: * What is highest dose of adaptive SBRT without causing serious side effects? * Can adaptive SBRT more precisely targeting the prostate while reducing radiation exposure to nearby organs? * What side effects do participants experience during treatment, right after treatment, and over the five years post-treatment? * Can adaptive SBRT reduce urination-related side effects and support quality of life during and after treatment? Participants will: * Receive adaptive SBRT treatment every other day, for a total of 5 treatment sessions (called fractions). The full course of treatment typically takes 2 to 3 weeks. * Have a follow-up phone call about 6 weeks after treatment to check on side effects and overall wellbeing. * Visit the clinic for check-ups and tests: * At 90 days (about 3 months) after treatment * Then every 3 months for the first year * Then every 6 months after that

Conditions Studied

Prostate Cancer (Adenocarcinoma)

Interventions

  • RADIATION adaptive stereotactic body radiation therapy (SBRT) with a SIB

Study Locations (1)

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2025-09-25
Est. Completion 2033-11-01
Phase NA

Sponsor

Fox Chase Cancer Center

183 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07219303

The ClinicalTrials.gov registry entry for NCT07219303 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 124-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (35% lower). The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer (Adenocarcinoma) appearing as the primary indexed condition, and to 1 intervention - of which adaptive stereotactic body radiation therapy (SBRT) with a SIB is the first listed.

NCT07219303 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT07219303 about?

NCT07219303 is a clinical study titled "Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer". The goal of this clinical trial is to evaluate if adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time. The main questions this trial aims to answer are: * What is highest do...

What is the current status of trial NCT07219303?

This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2025-09-25. Estimated completion is 2033-11-01.

What conditions does trial NCT07219303 study?

This clinical trial studies the following conditions: Prostate Cancer (Adenocarcinoma).

What interventions are being tested in trial NCT07219303?

The interventions under investigation include: adaptive stereotactic body radiation therapy (SBRT) with a SIB (RADIATION).

Who is sponsoring clinical trial NCT07219303?

This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07219303 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer (Adenocarcinoma)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer (Adenocarcinoma)

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.